ストックスクリーナーアプリを入手
115.48
0.47%
-0.54
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts - MarketBeat
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV - TradingView
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals EVP Jennifer Kayden Lee Executes Stock Options and Sells Shares Under 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals EVP Yann Mazabraud Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares - MarketBeat
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock - Investing.com
Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) EVP exercises 56,601 options and sells 75,834 shares - Stock Titan
Rhythm Pharmaceuticals (RYTM) EVP sells 57K shares after $6.80 option exercise - Stock Titan
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript - AOL.com
Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock By Investing.com - Investing.com South Africa
RYTM (NASDAQ: RYTM) investor plans sale of 5,079 shares worth $597K - Stock Titan
RYTM (RYTM) insider plans Form 144 sale of option and RSU shares - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Trading the Move, Not the Narrative: (RYTM) Edition - Stock Traders Daily
Rhythm Pharmaceuticals (RYTM) plans 57,000-share stock sale via broker - Stock Titan
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday? - TradingView
Rhythm Pharmaceuticals at Canaccord Genuity: launch gains widen - Investing.com
Bank of America Corp DE Grows Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (RYTM) insider outlines 10b5-1 stock sale plan in Form 144 - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
Rhythm Pharmaceuticals Announces UK MHRA Expansion of IMCIVREE for Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Orthofix Medical (OFIX), Rhythm Pharmaceuticals (RYTM) and Viatris (VTRS) - The Globe and Mail
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Rhythm Pharmaceuticals (RYTM) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
RHYTHM PHARMACEUTICALS, INC. SEC Filing (Aug 10, 2026) - stocktitan.net
J.P. Morgan Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $146 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Analyzing a 22.4% Potential Upside for This Biotech Innovator - DirectorsTalk Interviews
Assenagon Asset Management S.A. Invests $20.71 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (RYTM) Reports Promising RM 718 Data, Is The Upside Already Priced In? - Sahm
RYTM Maintained by JP Morgan -- Price Target Raised to $146 - GuruFocus
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $146.00 Price Target at JPMorgan Chase & Co. - MarketBeat
The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
California State Teachers Retirement System Acquires 12,269 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data - Sahm
Citigroup Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $160.00 - MarketBeat
RBC Adjusts Price Target on Rhythm Pharmaceuticals to $155 From $141, Maintains Outperform Rating - Moomoo
Rhythm Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-08-05 - Seeking Alpha
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - The Manila Times
Rhythm Pharmaceuticals reports RM-718 trial results in obesity - Investing.com
Rhythm Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $139.73, Implies 36% Upside - TradingView
Rhythm Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
RHYTHM PHARMACEUTICALS, INC. 2026: Revenue $71.26M, EPS ($0.73) — 10-Q Summary - TradingView
Rhythm Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results - MarketBeat
Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call - Benzinga
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rhythm Pharmaceuticals Q2 Net Loss Narrows, Revenue Rises - marketscreener.com
Is Rhythm Pharmaceuticals Inc (RYTM) Undervalued After Q2 Earnin - GuruFocus
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition - marketscreener.com
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
Q2 2026 Rhythm Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q2 Net Loss $0.73 a Share, vs. FactSet Est of $0.83 Loss - marketscreener.com
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand - TradingView
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update - The Manila Times
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity - The Manila Times
BRIEF-Rhythm Pharmaceuticals Q2 Net Income USD -49.298 Million Vs. IBES Estimate USD -55.5 Million - TradingView
Rhythm Pharmaceuticals Reports Preliminary Phase 2 RM-718 Data in Acquired Hypothalamic Obesity; Hosts Q2 2026 Conference Call - Quiver Quantitative
Rhythm Pharmaceuticals Announces Preliminary Data from - globenewswire.com
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):